Overarching Goals

  • Genovis will increase knowledge about biological processes that enable new and effective treatments and medicines.
  • Genovis will establish its products as the solution of choice in all analyses, from early discovery to production of tomorrow’s medications.
  • Genovis will create long-term shareholder value through results that generate both dividends for shareholders and funding for the continued innovative development of the Company.

Goals 2022

Financial Targets

  • Positive EBITDA.
  • Genovis will achieve annual organic sales growth of at least 25 percent.

Operational Objectives

  • Genovis will launch at least three products in 2022.
  • Establish Genovis products as quality control tools throughout the customer's value chain from discovery to drug production.
  • Establish sales in new application areas and geographic markets.
  • Svenska